



the **Hydroponics** company

[www.thcl.com.au](http://www.thcl.com.au)

ASX RELEASE (26<sup>th</sup> June 2018)

## Appointment of Product & Regulatory Affairs Manager

### Key Points:

- **Katy Williams Day appointed Product & Regulatory Affairs Manager**
- **Appointment underpins landing and distribution of Endoca's medicinal cannabis products in Australia**
- **20 years pharmaceutical products experience**
- **Management of future Australian manufactured products secured**

**The Hydroponics Company Limited** ("THC" or "the **Company**") is pleased to advise the appointment of Katy Williams Day as Product and Regulatory Affairs Manager in THC Pharma, a wholly owned subsidiary of THC.

Katy fills an essential role in THC as the Company commences the roll out of its first medicinal cannabis products into the Australian market from European-based Endoca.

Katy's career includes roles as Head of Medical Affairs, Head of Regulatory & Scientific Affairs, Director of Regulatory Affairs and Quality with organisations including Merck Serono, Phebra, Sandoz, Pfizer and Genzyme. Katy is also experienced in patient advocacy approaches critical to successful medicinal cannabis product adoption, and maintains active engagement in MS Angels, Rare Voices, Red Cross and other community-based patient support organisations.

Katy is qualified as a Master of Pharmacy with more than 20 years of experience in the regulatory, market, quality and clinical development of pharmaceutical products.

Katy will have a lead role in the introduction of Endoca products into the Australian market, as well as overseeing compliance and regulatory matters across THC Pharma operations. Katy will also leverage her extensive experience with TGA and international regulatory body submissions to progress THC Pharma's new product range, as manufacturing via its recently acquired pharmaceutical manufacturing facility comes online.

THC's Chairman, Steven Xu, said: "We are very pleased to welcome Katy to THC Pharma as a central part of our strategy to introduce Endoca's products into the Australian market. Katy's crossover experience in regulatory affairs and the challenges of new product introduction is exceptional, and highly suited Endoca and THC providing medicinal cannabis solutions to patients and their doctors in the near term."

The initial shipment of medicinal cannabis oils from Endoca will be accessible to patients and healthcare professionals in Australia through the MCMP [www.mcmp.com.au](http://www.mcmp.com.au).



The Hydroponics Company Limited  
(ASX: THC) ACN: 614 508 039

Suite 305, Level 3, 35 Lime Street,  
Sydney, NSW 2000 Australia.

For personal use only

**For further information, please contact:**

Henry Kinstlinger  
Joint Company Secretary

The Hydroponics Company Limited

Suite 305, Level 3, 35 Lime Street,  
Sydney, NSW 2000 Australia

**P:** +61 2 9251 7177

**E:** [henry.kinstlinger@thcl.com.au](mailto:henry.kinstlinger@thcl.com.au)



Michael Lovesey  
Director Corporate Media Relations

MMR Corporate Services Pty Ltd

Level 2, 131 Macquarie Street  
Sydney, NSW 2000 Australia

**P:** +61 2 9251 7177

**M:** +61 449 607 636

**E:** [michaell@mrmcorporate.com](mailto:michaell@mrmcorporate.com)

**Katy Williams Day**

Katy is qualified as a Master of Pharmacy with more than 20 years of experience in the regulatory, market, quality and clinical development of pharmaceutical products.

Katy's career includes roles as Head of Medical Affairs, Head of Regulatory & Scientific Affairs, Director of Regulatory Affairs and Quality with organisations including Merck Serono, Phebra, Sandoz, Pfizer and Genzyme. Katy is also experienced in patient advocacy approaches critical to successful medicinal cannabis product adoption, and maintains active engagement in MS Angels, Rare Voices, Red Cross and other community-based patient support organisations.

**About THC** [www.thcl.com.au](http://www.thcl.com.au)

THC is at the forefront of developing a leading, diversified worldwide cannabis business, focusing on two core business units: Development and delivery of medicinal cannabis, and manufacturing and distribution of hydroponics equipment, materials and nutrients.

**About Endoca** [www.endoca.com](http://www.endoca.com)

Endoca's primary focus is to research and develop innovative cannabis extracts that can help to balance the human Endocannabinoid system making them accessible world-wide. Through targeting the human Endocannabinoid System many people can be helped to restore their internal balance. Endoca is dedicated to producing the finest and purest quality products like CBD oil while never compromising on quality. Endoca also produces other cannabinoids as there are over 80 different in nature.

For personal use only